P1042: SAFETY AND TOLERABILITY RESULTS FROM THE PHASE 3B FREEDOM TRIAL OF FEDRATINIB (FEDR), AN ORAL, SELECTIVE JAK2 INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS (MF) PREVIOUSLY TREAT...

por Gupta, V., Yacoub, A., Verstovsek, S., Mesa, R. A., Harrison, C. N., Barosi, G., Kiladjian, J.-J., Deeg, H. J., Fazal, S., Foltz, L., Mattison, R. J., Miller, C. B., Parameswaran, V., Hernandez, C., Zhang, J., Talpaz, M.
Publicado 2022